Erasca, Inc. (ERAS) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
6.02
↑+211% vs avg
5yr avg: 1.93
30Y Low1.0·High4.1
ROE
↑
-43.7%
↓+45% vs avg
5yr avg: -78.8%
30Y Low-217%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ERAS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Erasca, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $3.1B | $587M | $320M | $526M | $1.9B | — | — |
| Enterprise Value | $3.1B | $571M | $283M | $297M | $1.5B | — | — |
| P/E Ratio → | -15.80 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 6.02 | 1.39 | 1.01 | 1.28 | 4.06 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ERAS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
ERAS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -43.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -43.7% | -43.7% | -34.3% | -55.9% | -43.5% | -216.7% | — |
| ROA | -36.0% | -36.0% | -27.5% | -47.8% | -39.2% | -112.7% | -21.7% |
| ROIC | -39.2% | -39.2% | -45.9% | -124.7% | -117.2% | -2961.8% | — |
| ROCE | -42.7% | -42.7% | -33.9% | -52.6% | -42.6% | -133.3% | -25.2% |
ERAS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $68M exceeds total debt of $52M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.18 | 0.13 | 0.04 | 0.03 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.12 | -0.56 | -0.75 | -0.58 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -1.23 | — | — | — |
Net cash position: cash ($68M) exceeds total debt ($52M)
ERAS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Erasca, Inc.'s current ratio of 9.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.13x to 9.84x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 9.84 | 9.84 | 12.26 | 9.13 | 16.02 | 8.77 | 18.59 |
| Quick Ratio | 9.84 | 9.84 | 12.26 | 9.13 | 16.02 | 8.77 | 18.59 |
| Cash Ratio | 9.50 | 9.50 | 11.94 | 8.95 | 15.81 | 8.68 | 18.32 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
ERAS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Erasca, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $234M | $150M | $122M | $119M | $119M | $119M |
Peer Comparison
Compare ERAS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ERASYou | $3B | -15.8 | — | — | — | — | -43.7% | -39.2% | — |
 RVMD | $32B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 TNGX | $3B | -27.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See ERAS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ERAS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ERAS vs RVMD
Side-by-side business, growth, and profitability comparison vs Revolution Medicines, Inc..
Start ComparisonERAS — Frequently Asked Questions
Quick answers to the most common questions about buying ERAS stock.
What is Erasca, Inc.'s P/E ratio?
Erasca, Inc.'s current P/E ratio is -15.8x. This places it at the 50th percentile of its historical range.
What is Erasca, Inc.'s ROE?
Erasca, Inc.'s return on equity (ROE) is -43.7%. The historical average is -78.8%.
Is ERAS stock overvalued?
Based on historical data, Erasca, Inc. is trading at a P/E of -15.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.